Abbott Laboratories, based in North Chicago, is a healthcare giant with a market cap of $221.2 billion. The company offers a wide range of products in diagnostics, medical devices, nutrition, and generic medicines, employing 114,000 people worldwide.

Despite its mega-cap status, Abbott’s stock has dipped 9.3% from its three-year high. Over the past three months, ABT stock has fallen 2.9% compared to the S&P 500 Index, signaling a slight underperformance.

In the longer term, Abbott has shown muted gains, with a 13.2% increase year-to-date and 8.4% over the past 52 weeks. The stock is currently trading below its 50-day and 200-day moving averages, indicating a bearish trend.

Following mixed Q3 results, Abbott’s stock dropped 2.9%. Despite the net sales growth of 6.9% to $11.4 billion, the company missed consensus estimates. Adjusted EPS saw a 7.4% increase to $1.30, meeting expectations.

Analysts are bullish on Abbott’s long-term outlook, with a consensus “Strong Buy” rating and a mean price target of $146.69, suggesting a 14.6% upside potential from current levels. Abbott has lagged behind peers like Boston Scientific Corporation in recent performance.

Read more at Yahoo Finance: Is Abbott Laboratories Stock Underperforming the S&P 500?